SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
New appointments of Drs. Philip C. Amrein and Alex Kentsis Validate Lead Galinpepimut-S and SLS009 Programs as Company Approaches Key...
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the...
Follow-on study (“PoC 2”) builds on initial success in pancreatic cancer pain Ethics committee authorization supports platform expansion into visceral...
– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models...
Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal...
GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering from diseases caused by...
Application deadline is July 9, 2025 COLUMBIA, Md., June 4, 2025 /PRNewswire/ -- The Maryland Stem Cell Research Commission ("Commission")...
Business Activity Index at 50%; New Orders Index at 46.4%; Employment Index at 50.7%; Supplier Deliveries Index at 52.5% TEMPE, Ariz., June 4,...
New vendor-agnostic interoperability advancements in Oracle Randomization and Trial Supply Management enable drug pooling and seamless supply management automation across...
Leading oncology research organization adopts Veeva Clinical Platform to enhance study delivery PLEASANTON, Calif. and NASHVILLE, Tenn., June 4, 2025...
- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel,...
A large heart imaging study previously undertaken at Queen Mary University of London (QMUL) and Barts Health NHS Trust tested...
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,...
Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or...
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety...
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in...
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA...
Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of...